OraSure Technologies (OSUR): Progress for Zika & Microbiome, Raising PT - Jefferies

August 30, 2016 8:38 AM EDT
Get Alerts OSUR Hot Sheet
Price: $8.71 --0%

Rating Summary:
    12 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 20 | New: 54
Trade OSUR Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst, Brandon Coulliard, reiterated his Buy rating on shares of OraSure Technologies (NASDAQ: OSUR) after two major positive pipeline developments add greater confidence in near term revenue forecasts & scope for upside to current consensus estimates including: 1) HHS/BARDA contract for rapid Zika test; and 2) third-party study data from Human Longevity (genomics industry KOL) endorsing OSUR's OMNIgene-GUT sample collection device as the de-facto gold-standard for all future microbiome studies.

Additional upcoming catalysts include: 1) Finalization of major HCV test supply contract (~$18M over ~1 yr period); 2) 510(k) submission & approval of rapid Ebola antigen test; 3) Launch of major new consumer genomics testing service (new DNAG customer); 4) possible M&A activities.

The price target increases to $10 from $8.

For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.

Shares of OraSure Technologies closed at $8.66 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment